PSAT1 and ovarian carcinoma: The study aims to explore a novel approach for early-stage ovarian cancer treatment by computationally identifying and validating potential Traditional Chinese Medicine (TCM) inhibitors targeting PSAT1, which is a crucial enzyme in the serine biosynthesis pathway, essential for the growth and survival of cancer cells, particularly in the early stages of ovarian cancer.